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ABSTRACT
Ceftobiprole is a broad-spectrum cephalosporin with potent activity against staphylococci, includ-
ing those resistant to oxacillin, as well as against most Gram-negative bacilli including Pseudomonas 
aeruginosa. In this study, the in vitro activity of ceftobiprole and comparator agents was tested 
against bacterial isolates recently collected from Brazilian private hospitals. A total of 336 unique 
bacterial isolates were collected from hospitalized patients between February 2008 and August 2009. 
Each hospital was asked to submit 100 single bacterial isolates responsible for causing blood, low-
er respiratory tract or skin and soft tissue infections. Bacterial identification was confirmed and 
antimicrobial susceptibility testing was performed using CLSI microdilution method at a central 
laboratory. The CLSI M100-S21 (2011) was used for interpretation of the antimicrobial suscepti-
bility results. Among the 336 pathogens collected, 255 (75.9%) were Gram-negative bacilli and 81 
(24.1%) were Gram-positive cocci. Although ceftobiprole MIC50 values for oxacillin resistant strains 
were two-fold higher than for methicillin susceptible S. aureus, ceftobiprole inhibited 100% of tested 
S. aureus at MICs ≤ 4 μg/mL. Polymyxin B was the only agent to show potent activity against Acine-
tobacter spp. (MIC50/90, 0.5/1 μg/mL), and P. aeruginosa (MIC50/90, 1/2 μg/mL). Resistance to broad-
spectrum cephalosporins varied from 55.3-68.5% and 14.3-28.5% among E. coli and Klebsiella spp. 
isolates, respectively; with ceftobiprole MIC50 > 6 μg/mL for both species. Our results showed that 
ceftobiprole has potent activity against staphylococci and E. faecalis, which was superior to that of 
vancomycin. Our data also indicates that ceftobiprole demonstrated potency comparable to that 
of cefepime and ceftazidime against key Gram-negative species.
Keywords: cephalosporins; Brazil; Gram-negative aerobic bacteria; methicillin-resistant Staphy-
lococcus aureus.
INTRODUCTION 
Fourth-generation cephalosporins repre-
sent a valuable addition to the therapeu-
tic armamentarium since they have dem-
onstrated activity against Gram-negative 
bacilli, including Enterobacteriaceae and, 
as well as Gram-positive cocci such as Strep-
tococcus pneumoniae and methicllin-suceptible 
staphylococci. However, the lack of activity 
against methicillin-resistant staphylococci 
and extended-spectrum beta-lactamases 
(ESBL)-producing isolates has limited wider 
clinical use.1,2 According to the most recent 
SENTRY data report, Staphylococcus aureus 
(20.2%) and coagulase-negative staphylo-
cocci (CoNS; 14.5%) ranked as the first and 
second cause of bloodstream infections in 
Brazilian hospitals between 2005 and 2008.3 
S. aureus was also the most common cause 
of skin and soft tissue infections (28.1%) 
and was isolated from 24.9% of patients with 
pneumonia. In that study, 31.0% and 78.7% 
of S. aureus and CoNS showed resistance to 
methicillin. The limited number of approved 
drugs with activity against multidrug-re-
sistant bacteria such as methicillin-resistant 
S. aureus (MRSA) has increased the demand 
for new agents with a novel mechanism of 
action or an ability to overcome bacterial 
resistance.
Ceftobiprole is a pyrrolidinone-3-ylidene-
methyl cephalosporin with a broad-spectrum 
of activity against Gram-positive cocci and 
Gram-negative bacilli.4-6 The binding of 
ceftobiprole to penicillin-binding proteins 
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(PBPs) is a critical determinant of its antibacterial activ-
ity.4 Ceftobiprole demonstrated potent binding to PBPs 
from Gram-positive bacteria, including those with de-
creased β-lactam sensitivity, such as PBP2a in MRSA and 
PBP2x in penicillin-resistant S. pneumoniae (PRSP), in 
contrast to ceftriaxone. In Escherichia coli, ceftobiprole 
exhibited strong binding to the essential PBPs, PBP2 and 
PBP3. It also exhibited a binding profile similar to those 
of cefepime and ceftazidime in P. aeruginosa but with en-
hanced binding to PBP2. These binding profiles explain 
the broad-spectrum activity for ceftobiprole.5 In addition, 
in single-step and serial passage in vitro resistance devel-
opment studies, ceftobiprole demonstrated a low propen-
sity to select for resistant subpopulations.7,8 The purpose 
of this study was to assess the in vitro activity of ceftobi-
prole and comparator agents against Gram-positive cocci 
and Gram-negative bacilli, recently isolated from patients 
of Brazilian private hospitals.
MATERIAL AND METHODS
Participant medical centers
Four private hospitals participated of the INVITA-A-CEFTO 
Brazilian Study. The medical centers were located in four 
distinct Brazilian cities, Belo Horizonte, São Paulo, Rio de 
Janeiro and São Luís. Selection of the participant medi-
cal centers was based on the criteria that they should have 
preferentially ≥ 200 beds, at least one adult intensive care 
unit and located in cities with more than one million in-
habitants. 
Bacterial isolates
A total of 336 consecutive isolates of Gram-positive cocci 
and Gram-negative bacilli was submitted between Febru-
ary 2008 and August 2009. Each medical center was guid-
ed by protocol to submit Gram-positive cocci and Gram-
negative bacilli collected from patients with diagnosis of 
pneumonia (40 isolates being from 20 ventilator-assisted 
patients), bloodstream infections (40 isolates) and skin 
and soft-tissue infections (20 isolates), according to the 
Centers for Disease Control and Prevention (CDC) defini-
tions.9 One isolate per patient was evaluated. All isolates 
were identified at the participating institution by routine 
methodologies in use at each laboratory. Upon receipt at 
the central laboratory (UNIFESP, São Paulo), isolates were 
subcultured to ensure viability and purity. Confirmation 
of species identification was performed with the BD Phoe-
nix™ Automated Microbiology System (BD Diagnostics, 
MD, USA) or conventional methods, as required. 
Susceptibility testing
Antimicrobial susceptibility testing was performed by the 
broth microdilution method, following recommendations 
of the Clinical and Laboratory Standards Institute (CLSI).10 
Antimicrobial powders were obtained from the respective 
manufacturers and microdilution plates were prepared by 
TREK Diagnostics (West Sussex, England). Susceptibil-
ity results were interpreted according to CLSI document 
M100-S2111 for all comparison agents except for doripen-
em,12 tigecycline13 and ceftobiprole.14 Quality control was 
performed by testing E. coli ATCC 25922; P. aeruginosa 
ATCC 27853; S. aureus ATCC 29213 and E. faecalis ATCC 
29212.
RESULTS
A total of 336 isolates were collected as part of the 
INVITA-A-CEFTO Brazilian Study between Febru-
ary 2008 and August 2009. Of those, 225 (75.9%) and 81 
(24.1%) were classified as Gram-negative and Gram-pos-
itive, respectively. The bacterial isolates were collected 
mainly from patients diagnosed with bloodstream (38.4%), 
lower respiratory tract (39.9%) and skin and soft tissue 
(21.7%) infections. The frequency of isolates collected, ac-
cording to infection type and medical centers is shown in 
Table 1. The most frequent genera/species collected were 
Table 1. Frequencies of isolates collected by the INVITA-A-CEFTO study according to type of infection and  
medical center
 Medical center  Bloodstream Respiratory tracts Skin and soft tissue Total
 (city/state) infections infections infection
01 (São Paulo, SP) 40 34 20 94 (28.0%)
02 (Rio de Janeiro, RJ) 38 39 20 97 (28.9%)
03 (Belo Horizonte, MG) 24 21 15 60 (17.9%)
04 (São Luis, MA)  27 40 18 85 (25.3%)
Total  129 (38.4%) 134 (39.9%) 73 (21.7%) 336 (100%)
Ceftobiprole activity against Brazilian isolates
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Pseudomonas spp. (28.6%); Klebsiella spp. (12.2%); 
S. aureus (10.7%); Acinetobacter spp. (8.9%); E. coli 
(8.3%) and coagulase negative staphylococci (CoNS, 
6.8%). The frequency of occurrence of all pathogens col-
lected is shown in Table 2.
Antimicrobial activity of the tested agents and the 
susceptibility profile of the most frequent Gram-negative 
isolates are shown in Table 3. Ceftobiprole showed similar 
activity to that displayed by cefepime against P. aeruginosa, 
K. pneumoniae, A. baumannii, E. coli and Enterobacter spp. 
P. aeruginosa showed the highest rates of susceptibil-
ity towards polymyxin B (98.9%), amikacin (59.1%) and 
piperacillin/tazobactam (58.1%) (Table 3). Among the 
cephalosporins, slightly greater percentage of isolates 
was inhibited at MICs ≤ 8 μg/mL by ceftazidime (48.4%) 
or cefepime (47.8%) than by ceftobiprole (36.8%). Cefto-
biprole and ceftriaxone inhibited 36.8% of K. pneumo-
niae isolates at concentrations ≤ 8 μg/mL. Against this 
species, ceftobiprole activity was comparable to that 
displayed by cefepime (39.5%), but lower than that of 
ceftazidime (44.7%, Table 4). Among the carbapen-
ems, meropenem (76.3% susceptibility) and doripenem 
(73.7% susceptibility) showed remarkable susceptibil-
ity rates, followed by imipenem (68.4% susceptibility). 
Moreover, imipenem (MIC90, 4 μg/mL) was two-fold 
more potent than meropenem (MIC90, 8 μg/mL) and 
doripenem (MIC90, 8 μg/mL) against K. pneumoniae iso-
lates. All tested K. pneumoniae isolates were susceptible 
to tigecycline. Levofloxacin resistance was observed in 
47.4% of K. pneumoniae isolates.
All tested A. baumannii isolates were susceptible to 
tigecycline (MIC90, 0.5 μg/mL) and polymyxin B (MIC90, 
≤ 0.5 μg/mL). Ceftobiprole had MIC50/90, > 6 μg/mL as did 
cefepime and ceftazidime. 
The potency of ceftobiprole (MIC50, 0.5 μg/mL) was iden-
tical to those displayed by ceftazidime (MIC50, 0.5 μg/mL) 
and cefepime (MIC50, 0.5 μg/mL) among E. coli isolates. 
Against Enterobacter spp., cefepime (MIC50, ≤ 0.12 μg/mL) 
was at least two-fold and four-fold more active than cefto-
biprole (MIC50, 0.25 μg/mL) and ceftazidime (MIC50, 
0.5 μg/mL), respectively. Nevertheless, the highest in vitro 
activity for ceftobiprole was observed for this genus. Ap-
proximately 68% and 76% of E. coli and Enterobacter spp., 
respectively, were inhibited by ceftobiprole at 8 μg/mL 
(Table 4). 
The activity of ceftobiprole and other antimicrobial 
agents tested against Gram-positive isolates is shown in 
Tables 5 and 6. Overall, 33.3% of S. aureus isolates were re-
sistant to oxacillin. Ceftobiprole was two-fold more potent 
against oxacillin-susceptible S. aureus (MIC50, 0.5 μg/mL) 
than oxacillin-resistant S. aureus (MIC50, 1 μg/mL). All 
S. aureus strains were inhibited by concentrations of cefto-
biprole ≤ 4 μg/mL. Agents providing the highest coverage 
against all S. aureus included vancomycin (MIC50, 1 μg/mL; 
100% susceptible), teicoplanin (MIC50, ≤ 2 μg/mL; 100% 
susceptible), linezolid (MIC50, 4 μg/mL; 97.2% susceptible) 
and tigecycline (MIC50, 0.25 μg/mL; 97.2% susceptible). 
Tigecycline (MIC50, 0.25 μg/mL; 100% susceptibility) fol-
lowed by ceftobiprole (MIC50/90, 1 and 8 μg/mL) were the 
most active agents tested against CoNS isolates. At 2 μg/mL, 
ceftobiprole inhibited 95.7% of CoNS isolates (Table 6). 
Only a single CoNS isolate showed a ceftobiprole MIC of 
8 μg/mL.
Ceftobiprole (MIC50/90, 0.5 and 16 μg/mL) inhibited the 
growth of 88.9% of the E. faecalis isolates at concentrations 
Table 2. Frequency of isolates collected by the 
INVITA-A-CEFTO Brazilian Study
Microorganism Number of isolates (%)
Pseudomonas spp.a 96 (28.6)
Klebsiella spp.b 41 (12.2)
Staphylococcus aureus 36 (10.7)
Acinetobacter baumannii 30 (8.9)
Escherichia coli 28 (8.3)
Staphylococcus coagulase negativac 23 (6.8)
Enterobacter spp.d 21 (6.3)
Enterococcus faecalis 18 (5.4)
Serratia spp.e 17 (5.1)
Morganella morgannii 4 (1.2)
Proteus mirabilis 4 (1.2)
Providencia stuartii 4 (1.2)
Streptococcus spp.f 4 (1.2)
Stenotrophomonas maltophilia 3 (0.9)
Burkholderia cepacea 2 (0.6)
Achromobacter xylosoxidans 1 (0.3)
Aeromonas hydrophila 1 (0.3)
Citrobacter koseri 1 (0.3)
Cryseobacterium gleum 1 (0.3)
Moraxella spp. 1 (0.3)
Total 336
aP. aeruginosa (94), P. putida (1), P. fluorescens (1).
bK. pneumoniae (38), K. oxytoca (3).
cS. epidermidis (15), S. haemolyticus (2), S. hominis (2),  
S. capitis (1), Staphylococcus spp. (3).
dE. cloacae (10), E. aerogenes (9), E. cancerogenus (1),  
E. sakazakii (1). Recentely, E. sakazakii was called Cronobac-
ter sakazakii.
eS. marcescens (14), S. plymuthica (3).
fS. mitis (1), S. agalactiae (3). 
Cereda, Azevedo, Girardello et al.
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Table 3. In vitro activity of ceftobiprole in comparison to selected antimicrobial agents tested against the main 
Gram negative pathogens collected by the INVITA-A-CEFTO Brazilian Study
Organism/                     MIC (µg/mL)
Antimicrobial agentsa MIC50 MIC90 Susceptible (%) Resistant (%)
P. aeruginosa (94) 
 Ceftobiprole > 16 > 16 15.1c 84.9c
 Ceftazidime 16 > 16 48.4 45.2
 Cefepime 16 > 16 47.3 43.0
 Aztreonam 16 > 16 32.3 50.5
 Piperaracillin/Tazobactam 64 > 64 58.1 41.9
 Doripenemb 4 > 16 40.9 -f
 Meropenem 8 > 8 43.6 46.8
 Imipenem 8 > 8 43.0 44.1
 Ciprofloxacin > 2 > 2 37.6 59.1
 Levofloxacin > 4 > 4 34.4 59.1
 Amikacin 16 > 32 59.1 37.6
 Polymyxin B 1 2 98.9 1.1 
K. pneumoniae (38)    
 Ceftobiprole > 16 > 16 31.6c 68.5c
 Cefoxitin 8 > 16 60.5 31.6
 Ceftriaxone > 32 > 32 28.9 68.5
 Ceftazidime > 16 > 16 42.1 55.3
 Cefepime > 16 > 16 39.5 57.9
 Aztreonam > 16 > 16 42.1 55.3
 Piperaracillin/Tazobactam 64 > 64 39.5 52.6
 Doripenemb 0.25 8 73.7 23.6
 Meropenem 0.12 8 76.3 21.1
 Imipenem 1 4 68.4 13.2
 Ciprofloxacin > 2 > 2 34.2 63.2
 Levofloxacin 4 > 4 39.5 47.4
 Amikacin 8 32 84.2 2.6
 Polymyxin Be ≤ 0.5 1 100.0 0.0
 Tigecyclineb 1 2 100.0 0.0
A. baumannii (30)    
 Ceftobiprole > 16 > 16 20.0c 80.0c
 Ceftriaxone > 32 > 32 6.7 66.7
 Ceftazidime > 16 > 16 40.0 56.7
 Cefepime > 16 > 16 26.7 73.3
 Piperaracillin/Tazobactam > 64 > 64 16.7 76.7
 Doripenemb > 16 > 16 23.3 -f
 Meropenem > 8 > 8 23.3 76.7
 Imipenem > 8 > 8 23.3 76.7
 Ciprofloxacin > 2 > 2 20.0 80.0
 Levofloxacin > 4 > 4 20.0 76.7
 Amikacin > 32 > 32 43.3 56.7
 Polymyxin B ≤ 0.5 1 100.0 0.0
 Tigecyclineb 0.5 2 100.0 0.0
Ceftobiprole activity against Brazilian isolates
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Table 3. In vitro activity of ceftobiprole in comparison to selected antimicrobial agents tested against the main 
Gram negative pathogens collected by the INVITA-A-CEFTO Brazilian Study
Organism/                     MIC (µg/mL)
Antimicrobial agentsa MIC50 MIC90 Susceptible (%) Resistant (%)
E. coli (28)    
 Ceftobiprole 0.5 > 16 57.1c 39.2c
 Cefoxitin ≤ 4 > 16 82.1 14.3
 Ceftriaxone 1 > 32 64.3 28.5
 Ceftazidime 0.5 16 78.6d 17.8
 Cefepime 0.5 > 16 78.6 14.3
 Aztreonam ≤ 1 > 16 75.0 14.3
 Piperaracillin/Tazobactam 4 16 92.9 7.1
 Doripenemb ≤ 0.12 1 96.4 3.57
 Meropenem ≤ 0.12 0.25 100.0 0.0
 Imipenem 0.25 2 89.3 0.0
 Ciprofloxacin 2 > 2 46.4 50.0
 Levofloxacin 2 > 4 50.0 46.4
 Amikacin ≤4 > 32 85.7 10.7
 Polymyxin Be ≤ 0.25 1 100.0 0.0
 Tigecyclineb 0.25 1 100.0 0.0
Enterobacter spp. (21)    
 Ceftobiprole 0.25 > 16 76.2c 23.8c
 Ceftriaxone  1 > 32 71.4 28.6
 Ceftazidime 0.5 > 16 76.2 23.8
 Cefepime ≤ 0.12 > 16 76.2 23.8
 Aztreonam ≤ 1 > 16 66.7 28.6
 Piperaracillin/Tazobactam 4 > 64 76.2 19.0
 Doripenemb 0.5 2 85.7 9.52
 Meropenem 0.12 1 90.5 0.0
 Imipenem 4 4 28.6 57.2
 Ciprofloxacin ≤ 0.25 > 2 81.0 19.0
 Levofloxacin ≤ 0.5 > 4 81.0 19.0
 Amikacin ≤ 4 16 90.5 9.5
 Polymyxin Be 1 > 4 71.4 23.8
 Tigecyclineb 0.5 2 95.2 0.0
aMIC determined according CLSI (2009) recommendations.
bResistance rates calculated according CLSI M100-S21 document (2011), except for doripenem and tigecycline, which were calcu-
lated according the FDA criteria.
cInterpretative criteria according to Rossolini et al.14
dAccording to breakpoints established by CLSI for P. aeruginosa (≤ 2 µg/mL for susceptibility and ≥ 8 µg/mL for resistance).
eAccording P. aeruginosa breakpoint, CLSI 2009 recommendations.
fInterpretative criteria not established by CLSI or FDA.
Cereda, Azevedo, Girardello et al.
Braz J Infect Dis 2011; 15(4):339-348
BJID-4-JUN ARTE FINAL.indd   343 28/07/11   13:31
344
of 1 μg/mL even though enterococci are generally not inhib-
ited by cephalosporins. Only two (20.2%) E. faecalis strains 
isolated from a single medical center presented ceftobi-
prole MICs ≥ 16 μg/mL (data not shown). Among the 
E. faecalis isolates tested, 94.4% were susceptible to am-
picillin, vancomycin and teicoplanin, representing the 
highest susceptible rates (Table 5). One linezolid-resistant 
E. faecalis isolate (5.6%) was isolated from a patient diag-
nosed with skin and soft tissue infection.
DISCUSSION 
The aim of this study was to assess the activity of ceftobi-
prole, a new broad-spectrum cephalosporin, against con-
temporary Gram-positive and Gram-negative pathogens 
collected from patients hospitalized at four distinct Bra-
zilian medical centers, as part of the INVITA-A-CEFTO 
Brazilian Study. 
Ceftobiprole was highly potent against all staph-
ylococcal isolates, inhibiting 100% of CoNS and 
S. aureus at MICs ≤ 8 μg/mL and ≤ 4 μg/mL, respec-
tively. MIC90 values for MRSA were eight-fold high-
er than those for MSSA isolates (Table 5). These re-
sults were similar to those previously reported.7,15,16 
Although cephalosporins are generally inactive against 
E. faecalis, ceftobiprole inhibited 88.9% at MICs 
≤ 4 μg/mL.
Ceftobiprole showed similar potency to those 
of 3th- and 4th-generation cephems (MIC50 values, 
0.25 ≥ 16 μg/mL) for the main Enterobacteriaceae spe-
cies. All cephaloporins demonstrated poor activity 
against K. pneumoniae (28.9-42.1% susceptible). This 
fact could be explained by the probable high rate of 
ESBL-producing K. pneumoniae isolates in Brazilian 
hospitals and since ceftobiprole is hydrolyzed by class 
A, B, and D extended-spectrum beta-lactamases, but not 
by class C enzymes, as previously reported.17 Ceftobi-
prole, like cefepime, is a weak inducer and a poor sub-
strate for AmpC β-lactamases.1,17
Ceftobiprole like ceftazidime and cefepime 
(MIC50/90 ≥ 16 μg/mL, Table 3) showed poor in vit-
ro activity against P. aeruginosa and Acinetobac-
ter spp. isolates. Polymyxin was the only antimi-
crobial agent to show good activity against both 
P. aeruginosa and Acinetobacter spp. isolates. The el-
evated carbapenem resistance rates noticed among 
P. aeruginosa and Acinetobacter spp. tested in this study 
could be possibly attributed to the spread of clones that 
produce SPM-1 and OXA-23, respectively, in Brazilian 
hospitals, as noticed before.18,19
Despite the low number of isolates collected, the re-
sistance rates to oxacillin among staphylococci appeared 
to be similar to those previously reported in a Brazil-
ian study.3 Curiously, the antimicrobial resistance rates 
Ceftobiprole activity against Brazilian isolates
Table 4. Comparisons of cephalosporins tested against the major Gram-negative isolates collected by the 
INVITA-A-CEFTO Brazilian Study 
Organism (n) Antimicrobial       Cumulative % inhibited at MIC (µg/mL) 
 agents 0.12 0.25 0.5 1 2 4 8 16 32
P. aeruginosa (94) Ceftobiprole   1.1 2.1 6.3 14.7 36.8 45.3 100.0 
 Cefepime     5.3 30.5 47.8 56.8 100.0 
 Ceftazidime    2.1 7.4 35.8 48.4 54.7 100.0
K. pneumoniae (38) Ceftobiprole 21.1 28.9  31.6   36.8  100.0 
 Cefepime  28.9 34.2  36.8  39.5 42.1 100.0 
 Ceftazidime  21.1 28.9 34.2 39.5 42.1 44.7 100.0 
 Ceftriaxone 26.3  28.9  31.6  36.8 100.0 
A. baumannii (30) Ceftobiprole  10.0 16.7  20.0   30.0 100.0 
 Cefepime  3.3  10.0 20.0 23.3 26.7  100.0 
 Ceftazidime    3.3 6.7 26.7 40.0 43.3 100.0 
 Ceftriaxone     3.3  6.7 33.3 40.0
E. coli (28) Ceftobiprole  7.1 50.0 57.1  60.7 67.9  100.0 
 Cefepime  46.4 50.0  64.3 71.4 78.6 85.7 100.0 
 Ceftazidime  39.3 57.1 64.3 71.4 78.6 82.1 92.9 100.0 
 Ceftriaxone 7.1 60.7 89.3 92.9 100.0    
Enterobacter spp. (21) Ceftobiprole  66.7 76.2      100.0 
 Cefepime  61.9 71.4    76.2  100.0 
 Ceftazidime  38.1 71.4 76.2     100.0 
 Ceftriaxone  47.6  71.4  76.2   100.0
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Cereda, Azevedo, Girardello et al.
Table 5. In vitro activity of ceftobiprole in comparison to selected antimicrobial agents tested against the main 
Gram-positive pathogens collected by the INVITA-A-CEFTO Brazilian Study 
Organism/ Antimicrobial agent                             MIC (µg/mL)a
  MIC50 MIC90 Susceptible (%)b Resistant (%)b
Enterococcus faecalis (18) 
 Ceftobiprole 0.5 16 88.9d 11.1d
 Penicillin 4 > 8 88.9 11.1
 Ampicillin 1 2 94.4 5.6
 Erythromycin > 4 > 4 5.6 61.1
 Gentamicin > 8 > 8 66.7c 33.3c
 Linezolid 2 > 4 83.3 5.6
 Levofloxacin 4 > 4 44.4 44.4
 Tigecycline 0.25 0.5 66.7 -e
 Vancomycin 2 4 94.4 5.6
 Teicoplanin ≤ 2 ≤ 2 94.4 5.6
CoNS (23)    
 Ceftobiprole 1 8 95.7d 4.3d
 Penicillin > 8 > 8 8.7 91.3
 Ampicillin 8 > 8 8.7 91.3
 Oxacillin > 2 > 2 8.7 91.3
 Cephalothin 8 > 16 56.5 39.1
 Ceftriaxone > 32 > 32 26.1 60.9
 Cefepime > 16 > 16 39.1 52.2
 Levofloxacin > 4 > 4 21.7 73.9
 Clindamycin > 2 > 2 26.1 69.6
 Erythromycin > 4 > 4 17.4 73.9
 Gentamicin 2 > 8 56.5 39.1
 Linezolid 2 > 4 82.6 17.4
 Teicoplanin 4 > 16 82.6 17.4
 Vancomycin 2 4 95.7 4.3
 Tigecycline 0.25 0.5 100.0 -e
S. aureus (36)    
 Ceftobiprole 0.5 2 100.0d 0.0d
 Penicillin > 8 > 8 22.2 77.8
 Ampicillin > 8 > 8 19.4 80.6
 Cephalothin ≤ 4 > 16 77.8 16.7
 Ceftriaxone 4 > 32 69.4 13.9
 Cefepime 4 > 16 75.0 13.9
 Clindamycin ≤ 0.25 > 2 77.8 22.2
 Erythromycin 1 > 4 50.0 44.4
 Gentamicin ≤ 1 > 8 77.8 19.4
 Levofloxacin ≤ 0.5 > 4 77.8 22.2
 Linezolid 4 4 97.2 2.8
(Cont.)
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Table 5. In vitro activity of ceftobiprole in comparison to selected antimicrobial agents tested against the main 
Gram-positive pathogens collected by the INVITA-A-CEFTO Brazilian Study 
Organism/ Antimicrobial agent                             MIC (µg/mL)a
  MIC50 MIC90 Susceptible (%)b Resistant (%)b
S. aureus (36)
 Vancomycin 1 2 100.0 0.0
 Teicoplanin ≤ 2 > 16 100.0 0.0
 Tigecycline 0.25 0.5 97.2 -e
 Oxacillin 0.5 > 2 66.7 33.3
S. aureus oxacillin-resistant (12)  
 Ceftobiprole 1 4 100.0d 0.0d
 Penicillin > 8 > 8 8.3 91.7
 Ampicillin > 8 > 8 0 100
 Cephalothin 8 > 16 50.0 41.7
 Ceftriaxone 32 > 32 8.3 41.7
 Cefepime 16 > 16 25.0 41.7
 Clindamycin > 2 > 2 33.3 66.7
 Erythromycin > 4 > 4 8.3 83.3
 Gentamicin 2 > 8 66.7 25.0
 Levofloxacin > 4 > 4 33.3 66.7
 Linezolid 4 4 91.7 8.3
 Vancomycin 2 2 100.0 0.0
 Teicoplanin ≤ 2 > 16 100.0 0.0
 Tigecycline 0.25 0.5 91.7 -e
S. aureus oxacillin-susceptible (24)  
 Ceftobiprole 0.5 0.5 100.0d 0.0d
 Penicillin > 8 > 8 29.2 70.8
 Ampicillin > 8 > 8 29.2 70.8
 Cephalothin ≤ 4 ≤ 4 91.7 4.2
 Ceftriaxone 4 4 100.0 0.0
 Cefepime 2 4 100.0 0.0
 Clindamycin ≤ 0.25 ≤ 0.25 95.8 4.2
 Erythromycin ≤ 0.5 > 4 70.8 25.0
 Gentamicin ≤ 1 > 8 79.2 16.7
 Levofloxacin ≤ 0.5 ≤ 0.5 100.0 0.0
 Linezolid 4 4 100.0 0.0
 Tigecycline 0.25 0.5 100.0 -e
 Vancomycin 1 2 100.0 0.0
 Teicoplanin ≤ 2 ≤ 2 100.0 0.0
aMIC determined according CLSI (2009) recommendations.
bResistance rates calculated according CLSI M100-S21 (2011) document, except for tigecycline, for which the FDA criteria  
was used.
cSusceptible rates calculated considering the high level of gentamicin and streptomicin resistance. 
dInterpretative criteria according to Rossolini et al.14 
eInterpretative criteria not established by CLSI or FDA.
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Table 6. Antimicrobial activity of ceftobiprole tested against E. faecalis, S. aureus, and CoNS isolates collected 
from hospitalized patients as part of the INVITA-A-CEFTO Brazilian Study
Organism (No. tested)                       Cumulative % inhibited at MIC (µg/mL) 
  ≤ 0.12 0.25 0.5 1 2 4 8 ≥ 16
E. faecalis (18)   33.3 61.1 88.9 88.9 88.9 88.9 100.0
CoNS (23)  4.3 17.4 30.4 52.2 95.7 95.7 100.0 
Staphylococcus aureus (SA, 36)   16.7 72.2 83.3 94.4 100.0  
Oxacillin-susceptible SA (24)   25.0 100.0     
Oxacillin-resistant SA (12)     16.7 50.0 83.3 100.0  
observed among Gram-negative bacilli isolates collected 
from private hospitals were higher than those previous-
ly reported by other surveillance studies that evaluated 
bacterial isolates mostly collected from public/teaching 
hospitals.20
There has been a dramatic rise in antibiotic resistance in 
the hospital setting in the past decade. MRSA and carbap-
enem-resistant Gram-negative bacilli are of particular con-
cern.6 There is an urgent need to expand treatment options 
for treating infections caused by these pathogens. The activity 
of ceftobiprole against the S. aureus and CoNS isolates studied 
was good and warrant continued evaluation of ceftobiprole as 
therapy for severe infections, including skin and soft tissue in-
fections, especially in those institutions/regions where MRSA 
is highly prevalent.
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